当前位置:首页 >财报库 > 报告详情

再鼎医药Zai Lab Limited(ZLAB)2025年第二季度财报(10-Q)「NASDAQ」(英文版)(71页).pdf

上传人: 1****1 编号:970100 2025-09-18 71页 684.92KB

下载:

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,DC 20549_FORM 10-Q_(Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 19For the quarterly period ended June 30,2025ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1

2、9For the transition period from _ to _Commission File Number:001-38205_ZAI LAB LIMITED(Exact Name of Registrant as Specified in its Charter)_Cayman Islands98-1144595(State or Other Jurisdiction of Incorporation or Organization)(I.R.S.Employer Identification No.)899 Halei RoadBuilding B,PudongShangha

3、iChina201203314 Main Street 4th Floor,Suite 100 Cambridge,MA,USA02142(Address of Principal Executive Offices)(Zip Code)+86 216163 2588+1 857 706 2604(Registrants Telephone Number,Including Area Code)_Securities registered pursuant to Section 12(b)of the Act:Title of each classTradingSymbol(s)Name of

4、 each exchangeon which registeredAmerican Depositary Shares,each representing 10 OrdinaryShares,par value$0.000006 per shareZLABThe Nasdaq Global MarketOrdinary Shares,par value$0.000006 per share*9688The Stock Exchange of Hong Kong Limited*Included in connection with the registration of the America

5、n Depositary Shares with the Securities and Exchange Commission.The ordinary shares arenot registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.Indicate by check mark whether the registrant(1)has filed all reports required to be

6、filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filingrequirements for the past 90 days.Yes No Indicate by check mark whether the registra

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,以下是Zai Lab Limited 2025年第二季度报告的简要概括: 1. **财务状况**:Zai Lab第二季度净收入为1091万美元,同比增长9%,主要得益于VYVGART、XACDURO和NUZYRA的销售增长。 2. **研发进展**:Zai Lab在多个研发项目中取得进展,包括ZL-1310获得FDA的快速通道资格,Bemarituzumab在FGFR2b阳性胃癌的III期临床试验中取得积极结果。 3. **产品候选**:Zai Lab拥有多个处于后期研发阶段的候选产品,包括ZL-6201和ZL-1222。 4. **合作伙伴关系**:Zai Lab与argenx合作,VYVGART Hytrulo获得FDA批准用于治疗重症肌无力和慢性炎症性脱髓鞘性多发性神经根神经病。 5. **财务预测**:Zai Lab预计未来将继续在研发和商业化活动中投入大量资金,以支持其产品管线的发展。
**商业产品表现如何**? **研发进展如何**? **财务状况如何**?
客服
商务合作
小程序
服务号
折叠